BioNTech SE (BNTX) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

Earnings Reports

• BioNTech (BNTX) Q1 2026: $1B Buyback and $500M Cost Cuts Signal Oncology Pivot
  May 05, 2026
• BioNTech (BNTX) Q4 2025: Oncology Pipeline Drives €613M BMS Collaboration Revenue Shift
  March 10, 2026
• BioNTech (BNTX) Q3 2025: BMS Collaboration Adds $700M, Anchoring Oncology Pipeline Transition
  November 03, 2025
• BioNTech (BNTX) Q2 2025: $3.5B BMS Milestone Deal Accelerates Oncology Pivot
  August 04, 2025
• BioNTech (BNTX) Q1 2025: Oncology R&D Spend Climbs 4% as BNT327 Moves Toward Pivotal Trials
  July 06, 2025
• BioNTech (BNTX) Q3 2024: Oncology Pipeline Expands With 10+ Phase 2/3 Trials, Fueling R&D Surge
  November 04, 2024
• BioNTech (BNTX) Q2 2024: R&D Spend Surges 57% as Late-Stage Oncology Pipeline Accelerates
  August 05, 2024
• BioNTech (BNTX) Q1 2024: R&D Spend Jumps 52% as Oncology Pipeline Accelerates Toward 10 Pivotal Trials
  May 06, 2024
• BioNTech (BNTX) Q4 2023: R&D Spend to Rise 44% as Oncology Pipeline Targets $10B+ Opportunity
  March 20, 2024

Browse all companies